UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
AMENDMENT NO. 1
TO
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 6, 2007
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware |
0-26642 |
87-0494517 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (801) 584-3600
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Page 1 of 4 pages
EXPLANATORY NOTE
This amendment is being filed solely to incorporate by reference into Item 8.01 of this Current Report on Form 8-K/A certain information in the Registrant’s earnings release included as Exhibit 99.1 to the Registrant’s Current Report on Form 8-K furnished earlier today. No changes have been made to the text of the earnings release.
| ITEM 2.02 | Results of Operations and Financial Condition |
On February 6, 2007, Myriad Genetics, Inc. (the “Company”) announced its financial results for the three and six months ended December 31, 2006. The earnings release is attached hereto as an exhibit to this Current Report on Form 8-K/A and is being furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K/A.
In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| ITEM 8.01 | Other Events |
In its earnings release dated February 6, 2007 attached hereto as Exhibit 99.1, the Company also provided an update on its lead therapeutic candidate, Flurizan™, under the heading “Update on Flurizan.” The Company hereby incorporates such information by reference into this Item 8.01 of this Current Report on Form 8-K/A. The portions of the press release incorporated by reference into Item 8.01 of this Current Report on Form 8-K/A are being filed pursuant to Item 8.01.
| ITEM 9.01 | Financial Statements and Exhibits. |
(d)
| Exhibit Number |
Description | |
| 99.1 | Earnings release dated February 6, 2007 for the three and six months ended December 31, 2006. | |
Page 2 of 4 pages
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MYRIAD GENETICS, INC. | ||||||
| Date: February 6, 2007 | By: | /s/ Peter D. Meldrum | ||||
| Peter D. Meldrum | ||||||
| President and Chief Executive Officer | ||||||
Page 3 of 4 pages
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Earnings release dated February 6, 2007 for the three and six months ended December 31, 2006. | |
Page 4 of 4 pages